Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS JUNE ISSUE PUBLISHED
  • JUNE 2020 Issue has been successfully launched on 1 June 2020.

Abstract

REVIEW ON-RHEUMATOID ARTHRITIS

Saba Shaikh*, Ravi Dubey, Dr.Y.M Joshi and Dr. Vilasrao J. Kadam

Department of Pharmacology, Bharati Vidyapeeth’s College of Pharmacy, Sector 8, C.B.D., Belapur, Navi Mumbai 400614, Maharashtra, India.

ABSTRACT

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of the tissue around the joints,as well as in other organs in the body.Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors are involve in the diagnosis and prognosis of rheumatoid arthritis.RA traditionally been treated using pyramid approach,in which non-steroidal anti-inflammatory (NSAIDs) are the first line treatment and disease modifying anti-rheumatic drugs (DMARDs) are introduced relatively late in the disease.The treatment of RA has been revolutionized by advances in the understanding of its pathologic mechanisms and the development of drugs which target them.Biologic therapies have provided clear advance in the treatment of rheumatological conditions.Currently available TNF-targeting biologic agents that are licensed for at least one of the above-named diseases are etanercept, infliximab, adalimumab, golimumab, and certolizumab.Biologic agents with a different mechanism of action have also been approved in rheumatoid arthritis (rituximab, abatacept, and tocilizumab).Although these biologic agents are highly effective,there is a need for improved management strategies. Researchers are also developing molecules–for example,the Janus kinase inhibitor CP-690550 (tofacitinib) to target other aspects of the inflammatory cascade.

Keywords: Rheumatoid arthritis, Biologic therapy, DMARDs, Kinase inhibitor,TNF inhibitors.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More